Opendata, web and dolomites

HIVACAR SIGNED

Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HIVACAR project word cloud

Explore the words cloud of the HIVACAR project. It provides you a very rough idea of what is the project "HIVACAR" about.

actual    stakeholders    hivacar    clinical    hiv    trial    conceived    life    obtaining    social    quality    patients    therapy    treatment    addition    viral   

Project "HIVACAR" data sheet

The following table provides information about the project.

Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER 

Organization address
address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 08036
website: http://www.idibaps.org/en_index.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 6˙822˙299 €
 EC max contribution 6˙685˙111 € (98%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme /RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) coordinator 1˙070˙050.00
2    ETHERNA IMMUNOTHERAPIES BE (NIEL) participant 969˙375.00
3    FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA ES (BARCELONA) participant 934˙375.00
4    AARHUS UNIVERSITET DK (AARHUS C) participant 816˙250.00
5    THE ROCKEFELLER UNIVERSITY NOT FOR PROFIT CORPORATION US (NEW YORK) participant 706˙250.00
6    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 459˙276.00
7    AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS ES (MADRID) participant 408˙063.00
8    ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS FR (PARIS) participant 316˙236.00
9    ZABALA INNOVATION CONSULTING, S.A. ES (MUTILVA ALTA NAVARRA) participant 273˙125.00
10    VRIJE UNIVERSITEIT BRUSSEL BE (BRUSSEL) participant 248˙360.00
11    ASPHALION SL ES (BARCELONA) participant 175˙000.00
12    EUROPEAN AIDS TREATMENT GROUP EV DE (DUSSELDORF) participant 150˙000.00
13    UNIVERSIDAD COMPLUTENSE DE MADRID ES (MADRID) participant 128˙750.00
14    AELIX THERAPEUTICS SL ES (BARCELONA) participant 30˙000.00
15    Simon Fraser University CA (BURNABY) participant 0.00

Mappa

 Project objective

The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4 T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIVACAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HIVACAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

EuroXpand (2018)

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction: EUROXPAND

Read More  

NORMOPERF (2018)

Normothermic Perfusion Device for Renal and Hepatic Preservation and Viability Assessment

Read More  

OSTEOproSPINE (2018)

Novel Bone Regeneration Drug Osteogrow: Therapeutic Solution for Lumbar Back Pain

Read More